Re: Hopefully DM's exuberance is justified in the secondary endpoints

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Hopefully DM's exuberance is justified in the secondary endpoints

in response to

Hopefully DM's exuberance is justified in the secondary endpoints

chicagoest

posted on Nov 18, 2019 10:34AM

Wrong board Chicagoest. I think you meant to post this on RVX.

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply